Vertex Sits On $1.4bn Cash, Seeks External Innovation Away From CF
Executive Summary
Vertex – a company currently leading the lucrative cystic fibrosis market and set to retain command of this arena into the foreseeable future – is preparing to replicate its CF success in another therapy area.
You may also be interested in...
Vertex Cystic Fibrosis Forecast Brightens, With Gloomy Prospects For Competition
Vertex continued its growth story in cystic fibrosis during 2017. It also chose a pair of candidates for Phase III triple combination development, threatening to virtually seal off market entry to others.
Infographic: Top 100 Pharma Companies
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
Snapshot: April Highlights
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.